Dosage

Dosage and administration in peptide research protocols

A consolidated summary of the routes, concentration ranges and cycling patterns reported in published peptide research protocols, gathered from across the individual peptide and protocol pages on this site.

This page summarises dosing and administration conventions as they appear in published research literature and in informal research-peptide-community discussion. It is not clinical dosing advice, it is not a recommendation to administer any peptide to a human being, and it should not be treated as equivalent to a prescribing reference. Every figure referenced in the individual peptide entries linked from this page originates from a cited animal study, in vitro protocol or, where available, a registered human clinical trial — not from an internal recommendation of this site.

The compounds discussed across this site are, without exception, supplied for laboratory and research use only. None of them is a licensed medicine in the United Kingdom, and the dosing conventions summarised below describe what has been reported in published protocols, not what is safe, effective or appropriate for any individual's circumstances. Where a range is given, it reflects the span reported across cited studies for a given category, which frequently differ from each other in species, route, formulation and study objective; it is not a single validated figure.

Because of this, the page is deliberately structured around categories and routes rather than single numeric doses. Specific concentration figures, where documented in the literature, are kept on the individual peptide pages alongside their source citation, so that a reader can trace any number back to the study it came from rather than treating a bare figure on an aggregator page as authoritative.

Administration routes

Subcutaneous injection is the dominant route across nearly all peptide categories discussed on this site, reflecting the fact that most research peptides are large enough to have poor oral bioavailability and are broken down by gastrointestinal proteases if swallowed. It is the route most commonly reported in both animal studies and the informal research-peptide literature for GH-axis, pineal-axis, immune and recovery-focused compounds.

Intramuscular injection appears in the literature for a subset of compounds, including some BPC-157 and TB-500 protocols and parts of the SS-31 clinical-development programme, generally where faster absorption or a specific tissue-proximity rationale is described.

Intranasal administration is reported for a small number of compounds (Semax and Selank being the clearest examples on this site) where the original Russian research programmes developed nasal formulations specifically to bypass first-pass hepatic metabolism and access central nervous system targets more directly.

Intravenous administration appears principally in formal clinical-trial settings — for example, parts of the SS-31/elamipretide development programme and some early DSIP research — where controlled infusion rates and immediate bioavailability are experimentally required.

Topical application is reported for GHK-Cu specifically, reflecting its extensive use in published cosmetic-dermatology research and its CPNP cosmetic notification in the UK, distinct from its parenteral use in preclinical repair studies.

Typical research-protocol conventions by peptide category

GH-axis peptides (GHRH analogues and GHRPs)

Sermorelin, CJC-1295, Ipamorelin

Typical route: Subcutaneous injection is the overwhelmingly dominant route in published protocols, typically self-administered into abdominal subcutaneous tissue.
Concentration range: Published research protocols vary considerably by compound and study design; consult the individual peptide entries for the specific ranges reported in the cited literature rather than relying on a generic figure here.
Cycling pattern: Where cycling is discussed, it typically follows an evening-dosing pattern intended to align with the body's natural nocturnal GH-pulse, often with periodic breaks referenced in the literature to limit desensitisation of pituitary responsiveness.

Pineal-axis and gene-regulatory short peptides

Epitalon, Pinealon

Typical route: Subcutaneous or intraperitoneal injection in the published rodent literature; human cohort studies have also used subcutaneous administration.
Concentration range: Rodent protocols in the published literature report pulsed micrograms-per-kilogram dosing, and in vitro work reports low-nanomolar concentrations in culture medium. See the Epitalon and Pinealon entries for the specific figures reported in each cited study.
Cycling pattern: The distinctive feature of this category is short pulsed courses (days) repeated at intervals (often quarterly) rather than continuous daily administration — a pattern drawn from the original Khavinson-programme protocols and repeated across most subsequent published work.

Immune-restorative peptides

Thymosin Alpha-1, Thymalin

Typical route: Subcutaneous injection is standard in the licensed-elsewhere clinical literature (Thymosin Alpha-1 holds marketing authorisation in a number of non-UK jurisdictions for specific indications).
Concentration range: Clinical-literature dosing for licensed indications elsewhere differs from research-protocol dosing reported in longevity-focused sources; consult the individual peptide entry rather than assuming the two are interchangeable.
Cycling pattern: Published clinical protocols for licensed indications typically use twice-weekly dosing over extended courses; research-context discussions of immunosenescence applications sometimes describe shorter pulsed courses instead.

Tissue-repair and recovery peptides

BPC-157, TB-500, GHK-Cu

Typical route: Subcutaneous or intramuscular injection near the site of injury is most frequently described for BPC-157 and TB-500 in informal research-context discussion; GHK-Cu is additionally studied topically for skin applications and parenterally in preclinical models. Some BPC-157 gastrointestinal studies use oral gavage in animals.
Concentration range: Published rodent studies report low microgram-per-kilogram dosing for BPC-157; TB-500 human clinical-trial dosing (RegeneRx programme) differs from informal research-community dosing discussions. Refer to the individual peptide pages for the specific figures drawn from cited studies.
Cycling pattern: Recovery-context protocols discussed in the literature are typically framed around the expected tissue-repair timeline (weeks) rather than indefinite continuous administration, with courses ending or reassessed once the injury has resolved.

Mitochondrial peptides

MOTS-c, SS-31 (elamipretide)

Typical route: Subcutaneous injection for MOTS-c in published animal studies; SS-31 has been studied via subcutaneous, intravenous and intramuscular routes across its clinical development programme.
Concentration range: SS-31's clinical-trial dosing (from registered elamipretide trials) is publicly documented and differs materially from informal research-peptide dosing; MOTS-c dosing in the literature is drawn primarily from rodent metabolic studies. See each peptide's entry for the cited figures rather than a combined figure here.
Cycling pattern: Continuous or near-daily administration is more typical of this category than the pulsed-course pattern seen in pineal-axis peptides, reflecting the metabolic and mitochondrial-maintenance framing of the underlying research.

Sleep-architecture peptides

Epitalon, DSIP, Pinealon

Typical route: Subcutaneous injection in the available published literature for all three; DSIP has also been studied via intravenous administration in early research.
Concentration range: DSIP's original research used doses reported in the 1970s–1980s literature that predate modern reporting conventions; Epitalon and Pinealon ranges are covered under the pineal-axis category above. Consult the individual entries.
Cycling pattern: Sleep-context protocols in the literature generally mirror the pulsed-course pattern used elsewhere for pineal-axis peptides rather than nightly indefinite dosing.

Storage, reconstitution and handling

Lyophilised peptide and reconstituted peptide solution have very different stability profiles, and the reconstitution step is where most avoidable dosing errors originate — principally unit confusion between milligrams, micrograms and IU, and decimal-point misreads on vial labels. Rather than duplicate that material here, the full set of calculators and reference tables for reconstitution, dose-volume conversion, half-life modelling, molecular-weight lookup, concentration-unit conversion, storage shelf-life and syringe-unit conversion is maintained on the Tools page, which links through to the dedicated calculators on our sister site, ResearchPeptideCalculator.co.uk.

UK regulatory position

Every peptide discussed on this page and across this site is supplied in the United Kingdom as a research chemical for laboratory and preclinical use only. None holds an MHRA marketing authorisation for human therapeutic use, and supply for human consumption is not permitted under the Human Medicines Regulations 2012. This applies regardless of a compound's regulatory status elsewhere — for example, Thymosin Alpha-1's licensed status in some non-UK jurisdictions, or SS-31's active clinical-trial status, does not change its unlicensed research-only position in the UK.

None of the dosing or administration information summarised on this page constitutes authorisation, endorsement or encouragement of human use of any compound discussed. It is provided as a research-context reference to published literature conventions, consistent with the educational, non-clinical purpose of this site as a whole.